BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY : Impact Factor & More

eISSN: 1179-9889pISSN: 1179-9889
JournalOpen Access

Check your submission readiness

Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.

BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY Journal Specifications

Overview
Publisher DOVE MEDICAL PRESS LTD
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2390
Publication Time16
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2011
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 16
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY

Check if your research matches the topics covered in BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY?

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Check your research

FAQs on BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY

How long has BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY been actively publishing? Faqs

BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY has been in operation since 2011 till date.

What is the publishing frequency of BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY? Faqs

BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY published with a Continuous publication frequency.

How many articles did BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY publish last year? Faqs

In 2024, BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY publsihed 6 articles.

What is the eISSN & pISSN for BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY? Faqs

For BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, eISSN is 1179-9889 and pISSN is 1179-9889.

Who is the publisher of BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY? Faqs

DOVE MEDICAL PRESS LTD is the publisher of BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY.